Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-27. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
The Pacinian corpuscle (also lamellar corpuscle, or Vater–Pacini corpuscle) is a low-threshold mechanoreceptor, responsive to deep pressure, stretch, tickle and vibration, found in the skin and other internal organs. In the skin it is one of the four main types of cutaneous receptors. The corpuscles are present in skin notably on both surfaces of the hands and feet, arms, and neck. Pacinian corpuscles are also found on bone periosteum, joint capsules, the pancreas and other internal organs, the breast, genitals, and lymph nodes. Pacinian corpuscles are rapidly adapting mechanoreceptors. As phasic receptors they respond quickly but briefly to a stimulus with the response diminishing even when the stimulus is maintained. They primarily respond to vibration, and deep pressure. They are especially sensitive to high-frequency vibrations. Groups of corpuscles sense pressure changes (such as on grasping or releasing an object). They are additionally crucially involved in proprioception. The vibrational role may be used for detecting surface texture, such as rough and smooth.
In 1998, after 38 years of ownership, Monaghan announced his retirement, sold 93 percent of the company to Bain Capital, Inc. for about $1 billion, and ceased being involved in day-to-day operations of the company. A year later, the company named Dave Brandon as its CEO.
Severo-Kurilsky District (Severo-Kurilsk) Kurilsky District (Kurilsk) Yuzhno-Kurilsky District (Yuzhno-Kurilsk) Japan maintains a claim to the three islands of Kunashir, Iturup, and Shikotan, and the Habomai Islands, together called the Northern Territories. In addition, the Japanese government claims that the Kuril Islands, other than the Northern Territories and South Karafuto, are undetermined areas under international law because the San Francisco Peace Treaty does not specify where they belong and the Soviet Union did not sign it. On 8 February 2017 the Russian government gave names to five previously unnamed Kuril islands in Sakhalin Oblast: Derevyanko Island (after Kuzma Derevyanko, 43°22′8″N 146°1′3″E), Gnechko Island (after Alexey Gnechko, 43°48′5″N 146°52′1″E), Gromyko Island (after Andrei Gromyko, 46°14′1″N 150°36′1″E), Farkhutdinov Island (after Igor Farkhutdinov, 43°48′5″N 146°53′2″E) and Shchetinina Island (after Anna Shchetinina, 46°13′7″N 150°34′6″E).
Sources: en.wikipedia.org
Diski was a regular contributor to the London Review of Books; the collections Don't and Why Didn't You Do What You Were Told? collect articles and essays written for the publication. Her memoirs include In Gratitude, The Sixties, Skating to Antarctica, and Stranger on a Train: Daydreaming and Smoking around America With Interruptions, for which she won the 2003 Thomas Cook Travel Book Award. Benjamin Disraeli (1804–1881) novelist, poet, playwright, writer, and prime minister A prolific novelist, the 1840s Disraeli wrote a trilogy of novels with political themes. Coningsby attacks the evils of the Whig Reform Bill of 1832 and castigates the leaderless conservatives for not responding. Sybil; or, The Two Nations (1845) reveals Peel's betrayal over the Corn Laws. These themes are expanded in Tancred (1847). With Coningsby; or, The New Generation (1844). Isaac D'Israeli, (11 May 1766 – 19 January 1848) was a British writer, scholar and the father of British prime minister Benjamin Disraeli. He is best known for his essays and his associations with other men of letters. Michael Pinto-Duschinsky (born June 1943) Hungarian-born author, journalist, scholar, political consultant and writer. Anton Ehrenzweig (27 November 1908 – 5 December 1966) Austrian Jewish British author and theorist on modern art, psychoanalysis and Avant-garde music who wroteThe Psychoanalysis of Artistic Vision and Hearing (1953) and The Hidden Order of Art (1967).
== Discovery == Identified as a marker of epithelial differentiation upon its discovery in the 1990s, galectin-7 was first characterized for its increased expression in keratinocytes following UVB irradiation. Only later was its dual role in cancers recognized.
Freezing is an effective form of food preservation because the pathogens that cause food spoilage are either killed or do not grow very rapidly at reduced temperatures. The process is less effective in food preservation than are thermal techniques, such as boiling, because pathogens are more likely to be able to survive cold temperatures rather than hot temperatures. One of the problems surrounding the use of freezing as a method of food preservation is the danger that pathogens deactivated (but not killed) by the process will once again become active when the frozen food thaws. Foods may be preserved for several months by freezing. Long-term frozen storage requires a constant temperature of −18 °C (0 °F) or less.
Freeman returned to the screen in 2000 with the lead role of Charlie in the comedy Nurse Betty, featuring Renée Zellweger, Chris Rock, and Greg Kinnear. The film premiered at the Cannes Film Festival to mainly positive reviews; the critic from Variety magazine thought Freeman and Rock had "wonderful chemistry". Next, he appeared in Under Suspicion (2000), a thriller remake of the 1981 French film Garde à vue. The film had been "carting round" for twelve years before Freeman was able to produce it under Revelations Entertainment. He co-starred with Gene Hackman; "Working with Gene was wonderful. I didn't find it too hard working with an icon I so respected", Freeman said. Upon release, Under Suspicion was met with lukewarm reception; CNN's Paul Tatara praised the actors but thought the film was "too tawdry to be completely entertaining, and too static to generate much excitement".
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.